摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-methoxyhexadecanamide | 337962-52-4

中文名称
——
中文别名
——
英文名称
N-methoxyhexadecanamide
英文别名
Hexadecanoic acid methoxy-amide
N-methoxyhexadecanamide化学式
CAS
337962-52-4
化学式
C17H35NO2
mdl
——
分子量
285.47
InChiKey
HLQXLEOFBLMNDL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.9
  • 重原子数:
    20
  • 可旋转键数:
    15
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.94
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethynyl-1,2-benziodoxol-3(1H)-one 、 N-methoxyhexadecanamidepotassium carbonate 作用下, 以 1,2-二氯乙烷 为溶剂, 反应 24.0h, 以57%的产率得到(Z)-N-(1-vin-2-yl)-N-methoxyhexadecanamide-1,2-benziodoxol-3-(1H)-one
    参考文献:
    名称:
    异羟肟酸衍生物与乙炔基苯并恶唑啉酮的N-烯基化反应可通过乙烯基苯并恶唑啉酮合成顺式酰胺
    摘要:
    本文报道了在乙炔基苯并恶唑啉酮-乙腈络合物(EBX-MeCN)存在下,由O-烷基异羟肟酸立体合成顺式-β- N-烷氧基酰胺乙烯基苯并恶唑烷(顺式-β - N -RO-酰胺-VBXs)。反应在温和的条件下进行,所述条件包括水性溶剂,温和的碱和室温。该反应容许各种衍生自羧酸的O-烷基异羟肟酸,例如氨基酸,药物和天然产物。还使用氧化氘作为氘源合成了乙烯基双氘化的顺式-β - N -MeO-酰胺-VBXs。缬氨酸衍生的顺式将-β - N - MeO-酰胺-VBX立体定向衍生为异羟肟酸衍生的顺式-酰胺,而不会失去立体选择性或降低氘/氢比。
    DOI:
    10.1039/d1ob00055a
  • 作为产物:
    描述:
    棕榈酸氯化亚砜potassium carbonate 作用下, 以 乙酸乙酯 为溶剂, 反应 3.0h, 生成 N-methoxyhexadecanamide
    参考文献:
    名称:
    异羟肟酸衍生物与乙炔基苯并恶唑啉酮的N-烯基化反应可通过乙烯基苯并恶唑啉酮合成顺式酰胺
    摘要:
    本文报道了在乙炔基苯并恶唑啉酮-乙腈络合物(EBX-MeCN)存在下,由O-烷基异羟肟酸立体合成顺式-β- N-烷氧基酰胺乙烯基苯并恶唑烷(顺式-β - N -RO-酰胺-VBXs)。反应在温和的条件下进行,所述条件包括水性溶剂,温和的碱和室温。该反应容许各种衍生自羧酸的O-烷基异羟肟酸,例如氨基酸,药物和天然产物。还使用氧化氘作为氘源合成了乙烯基双氘化的顺式-β - N -MeO-酰胺-VBXs。缬氨酸衍生的顺式将-β - N - MeO-酰胺-VBX立体定向衍生为异羟肟酸衍生的顺式-酰胺,而不会失去立体选择性或降低氘/氢比。
    DOI:
    10.1039/d1ob00055a
点击查看最新优质反应信息

文献信息

  • Site Selectivity in the Synthesis of <i>O</i>-Methylated Hydroxamic Acids with Diazomethane
    作者:Antonella Leggio、Angelo Liguori、Anna Napoli、Carlo Siciliano、Giovanni Sindona
    DOI:10.1021/jo0012391
    日期:2001.4.1
    this paper we report the results obtained by treating some selected hydroxamic acids with diazomethane in ethereal media. The multitask reagent diazomethane was used either as a base to induce deprotonation of the chosen hydroxamic acids or as conjugated acid which undergoes one-pot methylation processes of the generated anions. Product distributions clearly showed that a high site selectivity is expressed
    在本文中,我们报告了通过在重介质中用重氮甲烷处理某些选定的异羟肟酸获得的结果。多任务试剂重氮甲烷既可以用作碱诱导所选的异羟肟酸去质子化,也可以用作共轭酸,该共轭酸经过一锅法对生成的阴离子进行甲基化。产物分布清楚地表明,在烷基化过程中,不同的去质子化物质表现出高的位点选择性。在所采用的条件下,在所有情况下,甲基化的普遍位点是异羟肟酸的氧。虽然在脂族异羟肟酸中仅观察到O-烷基化,但在芳族底物中,NH基团与OH的亲核位点竞争,尽管OH反应性仍然占主导地位。
  • Modifications of the Ethanolamine Head in <i>N</i>-Palmitoylethanolamine:  Synthesis and Evaluation of New Agents Interfering with the Metabolism of Anandamide
    作者:Séverine Vandevoorde、Kent-Olov Jonsson、Christopher J. Fowler、Didier M. Lambert
    DOI:10.1021/jm0209679
    日期:2003.4.1
    The endogenous fatty acid amide anandamide (AEA) has, as a result of its actions on cannabinoid and vanilloid receptors, a number of important pharmacological properties including effects on nociception, memory processes, spasticity, and cell proliferation. Inhibition of the metabolism of AEA, catalyzed by fatty acid amide hydrolase (FAAH), potentiates the actions of AEA in vivo and therefore may be a useful target for drug development. In the present study, we have investigated whether substitution of the headgroup of the endogenous alternative FAAH substrate palmitoylethanolamide (PEA) can result in the identification of novel compounds preventing AEA metabolism. Thirty-seven derivatives of PEA were synthesized, with the C16 long chain of palmitic acid kept intact, and comprising 20 alkylated, 12 aromatic, and 4 halogenated amides. The ability of the PEA derivatives to inhibit FAAH-catalyzed hydrolysis of [H-3]AEA was investigated using rat brain homogenates as a source of FAAH. Inhibition curves were analyzed to determine the potency of the inhibitable fraction (pI(50) values) and the maximal attained inhibition for the compound, given that solubility in an aqueous environment is a major issue for these compounds. In the alkylamide family, palmitoylethyl-amide and palmitoylallylamide were inhibitors of AEA metabolism with PI50 values of 5.45 and 5.47, respectively. Halogenated derivatives (Cl and Br) exhibit PI50 values of similar to5.5 but rather low percentages of maximal inhibition. The -OH group of the ethyl head chain of N-palmitoylethanolamine was not necessary for interaction with FAAH. Amides containing aromatic moieties were less potent inhibitors of AEA metabolism. Compounds containing amide and ester bonds, 13 and 37, showed PI50 values of 4.99 and 5.08, respectively. None of the compounds showed obvious affinity for CB1 or CB2 receptors expressed on Chinese hamster ovary (CHO) cells. It is concluded that although none of the compounds were dramatically more potent than PEA itself at reducing the metabolism of AEA, the lack of effect of the compounds at CB1 and CB2 receptors makes them useful templates for development of possible therapeutic FAAH inhibitors.
  • <i>N</i>-Alkenylation of hydroxamic acid derivatives with ethynyl benziodoxolone to synthesize <i>cis</i>-enamides through vinyl benziodoxolones
    作者:Daisuke Shimbo、Toshifumi Maruyama、Norihiro Tada、Akichika Itoh
    DOI:10.1039/d1ob00055a
    日期:——
    (cis-β-N-RO-amide-VBXs) from O-alkyl hydroxamic acids in the presence of an ethynyl benziodoxolone–acetonitrile complex (EBX–MeCN) is reported herein. The reaction was performed under mild conditions including an aqueous solvent, a mild base, and room temperature. The reaction tolerated various O-alkyl hydroxamic acids derived from carboxylic acids, such as amino acids, pharmaceuticals, and natural products
    本文报道了在乙炔基苯并恶唑啉酮-乙腈络合物(EBX-MeCN)存在下,由O-烷基异羟肟酸立体合成顺式-β- N-烷氧基酰胺乙烯基苯并恶唑烷(顺式-β - N -RO-酰胺-VBXs)。反应在温和的条件下进行,所述条件包括水性溶剂,温和的碱和室温。该反应容许各种衍生自羧酸的O-烷基异羟肟酸,例如氨基酸,药物和天然产物。还使用氧化氘作为氘源合成了乙烯基双氘化的顺式-β - N -MeO-酰胺-VBXs。缬氨酸衍生的顺式将-β - N - MeO-酰胺-VBX立体定向衍生为异羟肟酸衍生的顺式-酰胺,而不会失去立体选择性或降低氘/氢比。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物